10-Q: BiomX Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

BiomX Inc. reports its financial results for the quarter ended March 31, 2025, highlighting progress in its clinical programs and recent financing activities.

Summary

• BiomX Inc. reported a net loss of $7.659 million, or $0.33 per share, for the quarter ended March 31, 2025, compared to a net loss of $17.327 million, or $2.78 per share, for the same period in 2024.
• Research and development expenses, net of grants, were $5.250 million, an increase from $4.105 million in the prior year.
• General and administrative expenses decreased to $2.506 million from $2.680 million year-over-year.
• The company believes its current cash, cash equivalents, and restricted cash will be sufficient to meet working capital and capital expenditure requirements into the first quarter of 2026.
• BiomX is focusing on the development of BX004 for cystic fibrosis and BX211 for diabetic foot osteomyelitis.
• A Phase 2b study for BX004 in CF patients is expected to begin in the second quarter of 2025, with results anticipated in the first quarter of 2026 due to manufacturing delays.
• The company is planning for a phase 2/3 trial of BX211, pending FDA feedback and availability of cash resources.
• The company completed a registered direct offering and concurrent private placement in February 2025, raising gross proceeds of $5.5 million.
• The company entered into inducement letter agreements with certain warrant holders, resulting in gross proceeds of $6.5 million.
• The company had cash, cash equivalents, and restricted cash of approximately $21.2 million as of March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is still operating at a loss, there are positive developments in clinical trials and successful capital raising efforts. However, the going concern warning and manufacturing delays temper the positive aspects.

Positives

• The net loss decreased significantly from $17.327 million in Q1 2024 to $7.659 million in Q1 2025.
• The company has enough cash to fund operations into the first quarter of 2026.
• Positive results were achieved in the Phase 2 trial of BX211 for DFO.
• BX004 received Fast Track and orphan drug designation from the FDA.
• The company successfully raised capital through a registered direct offering and private placement in February 2025.

Negatives

• The company continues to operate at a loss, with a net loss of $7.659 million for Q1 2025.
• Manufacturing delays for BX004 have pushed back the expected study results to the first quarter of 2026.
• The company's ability to continue as a going concern is subject to substantial doubt.
• The company has accumulated a deficit of $188.4 million since its inception.

Risks

• The company's ability to raise additional capital is subject to market conditions and other factors.
• Increased research and development, clinical, or operating expenses may require additional funding or expense postponement.
• Disruptions due to the war with Hamas and Hezbollah, or Israeli political instability, could negatively affect the company's ability to access additional capital.
• The company's ability to generate revenue is uncertain, and it does not expect to generate significant revenues from sales of products in the next twelve months.

Future Outlook

BiomX expects its current cash resources to fund operations into the first quarter of 2026 and plans to continue focusing on the development of BX004 and BX211. The company anticipates initiating a Phase 2b study for BX004 in the second quarter of 2025 and is planning for a phase 2/3 trial of BX211, pending FDA feedback and availability of cash resources. The company expects to continue to incur additional losses in the foreseeable future and may require additional funding through various sources.

Industry Context

BiomX is operating in the competitive biotechnology industry, focusing on phage therapy for chronic diseases. The company's focus on cystic fibrosis and diabetic foot osteomyelitis addresses significant unmet medical needs. The company's progress in clinical trials and recent financing activities position it to advance its product candidates.

Comparison to Industry Standards

• It is difficult to compare BiomX's results directly to industry standards due to its unique focus on phage therapy and its stage as a clinical-stage company.
• Comparable companies in the biotechnology sector often have varying financial metrics depending on their stage of development, pipeline, and financing activities.
• For example, companies like Adaptive Phage Therapeutics (acquired by BiomX) and other phage therapy developers are not directly comparable due to differences in their clinical programs and financial structures.
• Industry benchmarks for R&D spending and clinical trial costs can vary widely depending on the therapeutic area and the stage of development.
• BiomX's focus on orphan drug designations and Fast Track status aligns with industry strategies to accelerate the development and approval of therapies for unmet medical needs.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial results will impact shareholder value.
• Employees: Cost-cutting measures and workforce reductions may affect employees.
• Patients: Progress in clinical trials for BX004 and BX211 could provide new treatment options for patients with cystic fibrosis and diabetic foot osteomyelitis.
• Creditors: The company's ability to raise additional capital will impact its ability to meet its financial obligations.

Next Steps

• Initiate a Phase 2b study in CF patients with chronic P. aeruginosa pulmonary infections in the second quarter of 2025.
• Plan for a phase 2/3 trial of BX211, pending FDA feedback and availability of cash resources.
• Continue discussions with the FDA and European Committee for Medicinal Products for Human Use regarding the potential to use Real-World Evidence to support potential future regulatory filings.
• Explore raising additional funds through public or private equity, debt financing, loans, government or other grants or collaborative agreements or from other sources.

Key Dates

Keywords

BiomX, financial results, cystic fibrosis, diabetic foot osteomyelitis, phage therapy, BX004, BX211, clinical trials, capital raise, R&D expenses, net loss, warrants